Press Releases

Year

Jun 27, 2019

Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

Global study designed to assess the efficacy and safety of suvodirsen in DMD patients amenable to exon 51 skipping Results intended to support regulatory approvals globally CAMBRIDGE, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines

Jun 12, 2019

Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference

CAMBRIDGE, Mass. , June 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Michael Panzara , MD, MPH, Chief Medical Officer,

May 22, 2019

Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass. , May 22, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

May 10, 2019

Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , May 10, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31,

Apr 16, 2019

Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019 Interim efficacy data from ongoing open-label extension study expected in H2 2019 Investor conference call scheduled

Apr 12, 2019

Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference

Suvodirsen Phase 1 Safety and Tolerability Results Accepted for Oral Presentation Investor Conference Call and Webcast Scheduled for Tuesday, April 16 CAMBRIDGE, Mass. , April 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to

Apr 10, 2019

Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs

Topline data readout from Huntington’s disease clinical trials now expected by year end 2019 CAMBRIDGE, Mass. , April 10, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling

Mar 25, 2019

Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference

CAMBRIDGE, Mass. , March 25, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlighting new data and

Mar 06, 2019

Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference

CAMBRIDGE, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

Mar 01, 2019

Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update

Outlines plans for building a fully integrated genetic medicines company CAMBRIDGE, Mass. , March 01, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases,